Longterm central venous access in gynecologic cancer patients
- 31 October 2000
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 191 (4) , 403-409
- https://doi.org/10.1016/s1072-7515(00)00690-6
Abstract
To assess the utility and safety of three different longterm indwelling intravenous catheters in patients with gynecologic malignancies. A retrospective review was performed of the records of all women with gynecologic malignancies who required longterm venous access catheters and ports between 1990 and 1997. Two hundred sixty-eight women underwent placement of 308 indwelling catheters, of which 305 were available for analysis. Of those, 68 (22%) were Hickman catheters, 162 (53%) were infusaports, and 75 (25%) were Peripheral Access System (PAS) ports. Venous access was obtained percutaneously in 152 (50%) patients and by cutdown in 153 (50%). Prophylactic anticoagulation was used with 96 catheters (31%). Catheter placement was associated with 12 (4%) immediate complications and 87 (29%) delayed complications. The average duration of a catheter in place was 5.6 months for the Hickman, 12.5 months for the infusaport, and 16.0 months for the PAS port (p < 0.001). Bacteremia was more likely to develop in patients with Hickman catheters when compared with those with infusaports and PAS ports (19% versus 6% and 5%, respectively, p = 0.002). Thrombosis was significantly less likely to develop in patients receiving prophylactic anticoagulation (11% versus 4%, p = 0.004). Overall, the complication rate was lower with cutdown versus percutaneous access (p = 0.004). There was no statistically significant difference between the frequency of complications when correlated with the stage of disease, patient age, body mass index, or type of malignancy. Infusaports and PAS ports were associated with a lower risk of infection and have a longer life than Hickman catheters. The cutdown approach was associated with a lower complication rate. Low-dose prophylactic anticoagulation should be given to all patients with longterm central venous catheters.Keywords
This publication has 15 references indexed in Scilit:
- Prevention of Thrombotic Disorders in Cancer Patients Undergoing ChemotherapyThrombosis and Haemostasis, 1997
- Obesity and prognosis in endometrial cancerAmerican Journal of Obstetrics and Gynecology, 1996
- An Evaluation of Groshong Central Venous Catheters on a Gynecologic Oncology ServiceGynecologic Oncology, 1995
- Experience with the Intravenous Totally Implanted Port in Patients with Gynecologic MalignanciesGynecologic Oncology, 1994
- Externalized Groshong Catheters and Hickman Ports for Central Venous Access in Gynecologic Oncology PatientsGynecologic Oncology, 1993
- A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients.Journal of Clinical Oncology, 1992
- Symptomatic central venous thrombosis and long-term right atrial cathetersGynecologic Oncology, 1990
- CLINICAL PERFORMANCE OF HICKMAN AND PORTACATH ATRIAL CATHETERSAnz Journal of Surgery, 1988
- Comparison of a Totally Implantable Access Device for Chemotherapy (Port-A-Cath) and Long-term Percutaneous Catheterization (Broviac)*Southern Medical Journal, 1988
- Catheter Replacement of the Needle in Percutaneous Arteriography: A new techniqueActa Radiologica, 1953